Sawai Pharmaceutical has reported a slight growth in its net sales and core operating income in Japan compared to the last fiscal year in its financial third quarter, despite facing ongoing challenges abroad and at home.
The Japanese giant’s domestic net sales grew by 10.4% to ¥136bn ($903.7m) in the first nine months of its financial year ending March 2024, compared to ¥123.2bn in the third quarter of the previous fiscal year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?